ES2187812T3 - Composicion de liposomas. - Google Patents
Composicion de liposomas.Info
- Publication number
- ES2187812T3 ES2187812T3 ES97940250T ES97940250T ES2187812T3 ES 2187812 T3 ES2187812 T3 ES 2187812T3 ES 97940250 T ES97940250 T ES 97940250T ES 97940250 T ES97940250 T ES 97940250T ES 2187812 T3 ES2187812 T3 ES 2187812T3
- Authority
- ES
- Spain
- Prior art keywords
- liposomes
- polynucleotide
- cationic
- composition
- dotap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A UNOS LIPOSOMAS CATIONICOS EN LOS CUALES EL POLINUCLEOTIDO ESTA CAPTADO DENTRO DEL ESPACIO INTRAVESICULAR. DICHOS LIPOSOMAS CONTIENEN COMPONENTES CATIONICOS COMO POR EJEMPLO, LIPIDOS CATIONICOS COMO EL DOTAP. PARA FORMAR ESTOS LIPOSOMAS, SE USA PREFERENTEMENTE UN PROCEDIMIENTO DE DESHIDRATACION-REHIDRATACION EN PRESENCIA DEL POLINUCLEOTIDO. PREFERENTEMENTE, ESTE POLINUCLEOTIDO CODIFICA DE UN MODO FUNCIONAL UN ANTIGENO CAPAZ DE PROVOCAR UNA REACCION INMUNITARIA DESEADA, ES DECIR UNA VACUNA GENICA.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619172.1A GB9619172D0 (en) | 1996-09-13 | 1996-09-13 | Liposomes |
GBGB9625917.1A GB9625917D0 (en) | 1996-12-13 | 1996-12-13 | Liposomes |
GBGB9713994.3A GB9713994D0 (en) | 1997-07-01 | 1997-07-01 | Liposomes |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2187812T3 true ES2187812T3 (es) | 2003-06-16 |
Family
ID=27268476
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97940250T Expired - Lifetime ES2187812T3 (es) | 1996-09-13 | 1997-09-15 | Composicion de liposomas. |
ES02016936T Expired - Lifetime ES2305157T3 (es) | 1996-09-13 | 1997-09-15 | Liposomas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02016936T Expired - Lifetime ES2305157T3 (es) | 1996-09-13 | 1997-09-15 | Liposomas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US7790696B2 (es) |
EP (2) | EP0938298B1 (es) |
JP (1) | JP2001502299A (es) |
KR (1) | KR100507660B1 (es) |
CN (1) | CN1138533C (es) |
AT (2) | ATE395904T1 (es) |
AU (1) | AU728581B2 (es) |
CA (1) | CA2271388C (es) |
DE (2) | DE69738719D1 (es) |
ES (2) | ES2187812T3 (es) |
WO (1) | WO1998010748A1 (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536344A (ja) * | 1999-02-05 | 2002-10-29 | ジエンザイム コーポレイション | 抗腫瘍免疫を発生させるためのカチオン性脂質の使用 |
CA2386024A1 (en) * | 1999-10-01 | 2001-04-12 | Lipoxen Technologies Limited | Liposome-entrapped dna oral vaccines |
WO2001041739A2 (en) | 1999-12-13 | 2001-06-14 | Lipoxen Technologies Limited | Liposomes |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
WO2004004758A1 (en) | 2002-07-05 | 2004-01-15 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
JP4546115B2 (ja) * | 2004-03-05 | 2010-09-15 | 三菱化学メディエンス株式会社 | 細胞中atpの定量法 |
DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
CN100400667C (zh) * | 2006-06-27 | 2008-07-09 | 浙江大学 | 脂质体包裹弓形虫pGRA4真核表达质粒的方法及用途 |
CA2687208C (en) | 2006-12-22 | 2017-02-14 | Soluciones Biotecnologicas Innovacion Ltda | Process and formulation for immunizing fish in aquaculture systems |
EP2184054A1 (en) | 2008-11-08 | 2010-05-12 | Lipoxen Technologies Limited | Small Interfering RNA Delivery |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
EP2451950B9 (en) * | 2009-07-06 | 2016-11-23 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
WO2011044545A2 (en) | 2009-10-09 | 2011-04-14 | Sigalov Alexander B | Methods and compositions for targeted imaging |
US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
JP5902616B2 (ja) * | 2010-04-28 | 2016-04-13 | 協和発酵キリン株式会社 | カチオン性脂質 |
ES2934240T3 (es) | 2010-07-06 | 2023-02-20 | Glaxosmithkline Biologicals Sa | Partículas de administración de tipo virión para moléculas de ARN autorreplicantes |
CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
CA2804492A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
MX343410B (es) | 2010-07-06 | 2016-11-04 | Novartis Ag * | Emulsiones cationicas de agua en aceite. |
PL3243526T3 (pl) | 2010-07-06 | 2020-05-18 | Glaxosmithkline Biologicals S.A. | Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych |
RS63949B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Pegilovani lipozomi za isporuku rnk koja kodira imunogen |
TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
BR112013017939B1 (pt) | 2011-01-13 | 2022-11-16 | Variation Biotechnologies Inc | Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma |
RU2491062C2 (ru) * | 2011-03-16 | 2013-08-27 | Общество С Ограниченной Ответственностью "Биотехнологии Пущино" | Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий |
NZ742420A (en) | 2011-05-24 | 2022-10-28 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Individualized vaccines for cancer |
BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
EP3332802A1 (en) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
CN103781470A (zh) | 2011-07-06 | 2014-05-07 | 诺华股份有限公司 | 包含核酸的水包油乳液 |
CN103796639B (zh) | 2011-07-06 | 2017-05-31 | 诺华股份有限公司 | 阳离子水包油乳液 |
WO2013104995A2 (en) | 2012-01-12 | 2013-07-18 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
AU2013213345A1 (en) | 2012-01-27 | 2014-08-28 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
BR112014030677A2 (pt) | 2012-06-08 | 2022-07-19 | Shire Human Genetic Therapies | distribuição pulmonar de mrna para células-alvo não-pulmonares |
AU2013351542B2 (en) | 2012-11-28 | 2018-08-09 | BioNTech SE | Individualized vaccines for cancer |
UA117008C2 (uk) | 2013-03-14 | 2018-06-11 | Шир Хьюман Дженетік Терапіс, Інк. | IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ |
EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
EP3501605B1 (en) | 2013-10-22 | 2023-06-28 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
CA2928186A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
WO2015100269A2 (en) * | 2013-12-27 | 2015-07-02 | Double Helix Corporation | Compositions and methods for providing active telomerase to cells in vivo |
BR112016016356B1 (pt) * | 2014-01-17 | 2023-12-26 | Fundació Institut Català De Nanociència I Nanotecnologia | Lipossoma, usos dos mesmos, e composição farmacêutica ou veterinária |
KR102470198B1 (ko) | 2014-04-25 | 2022-11-22 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
EP3892260A1 (en) * | 2020-04-10 | 2021-10-13 | Bayer Animal Health GmbH | Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids |
AU2022245985A1 (en) | 2021-03-22 | 2023-09-21 | Illumina Cambridge Limited | Methods for improving nucleic acid cluster clonality |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4515736A (en) | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
DE3582905D1 (de) | 1984-08-10 | 1991-06-27 | Syntex Inc | Stabile liposome mit wasserloeslichen arzneimitteln. |
ATE50983T1 (de) | 1985-01-07 | 1990-03-15 | Syntex Inc | Oberflaechenaktive n-(omega, omega-1-dialkoxy)und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,ntrisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen. |
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5545412A (en) | 1985-01-07 | 1996-08-13 | Syntex (U.S.A.) Inc. | N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4885172A (en) | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
JP2627899B2 (ja) * | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
US4882172A (en) * | 1988-04-08 | 1989-11-21 | Nabisco Brands, Inc. | System for processing chewing gum |
JP2923296B2 (ja) * | 1988-11-14 | 1999-07-26 | 株式会社ビタミン研究所 | 細胞への遺伝子導入法 |
ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) * | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
JP2958076B2 (ja) * | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
EP0625049A4 (en) | 1992-01-23 | 1995-07-12 | Vical Inc | EX VIVO GENTRANSFER. |
US6113946A (en) | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
WO1995004524A1 (en) * | 1993-08-06 | 1995-02-16 | Opperbas Holding B.V. | A method for high loading of vesicles with biopolymeric substances |
ATE164515T1 (de) * | 1993-11-05 | 1998-04-15 | Amgen Inc | Herstellung von liposomen und verfahren zur substanzverkapselung |
CN1099868C (zh) * | 1993-11-16 | 2003-01-29 | 斯卡法玛公司 | 具有控制释放活性成分作用的囊 |
IL112820A0 (en) * | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
IL122290A0 (en) * | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US5753235A (en) | 1996-02-15 | 1998-05-19 | Heska Corporation | Recombinant canine herpesviruses |
US7384923B2 (en) * | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
-
1997
- 1997-09-15 CN CNB971996741A patent/CN1138533C/zh not_active Expired - Fee Related
- 1997-09-15 DE DE69738719T patent/DE69738719D1/de not_active Expired - Lifetime
- 1997-09-15 AT AT02016936T patent/ATE395904T1/de not_active IP Right Cessation
- 1997-09-15 EP EP97940250A patent/EP0938298B1/en not_active Expired - Lifetime
- 1997-09-15 KR KR10-1999-7002103A patent/KR100507660B1/ko not_active IP Right Cessation
- 1997-09-15 JP JP10513398A patent/JP2001502299A/ja not_active Ceased
- 1997-09-15 CA CA002271388A patent/CA2271388C/en not_active Expired - Fee Related
- 1997-09-15 AT AT97940250T patent/ATE228824T1/de not_active IP Right Cessation
- 1997-09-15 EP EP02016936A patent/EP1254657B1/en not_active Expired - Lifetime
- 1997-09-15 WO PCT/GB1997/002490 patent/WO1998010748A1/en active IP Right Grant
- 1997-09-15 DE DE69717661T patent/DE69717661T2/de not_active Expired - Lifetime
- 1997-09-15 ES ES97940250T patent/ES2187812T3/es not_active Expired - Lifetime
- 1997-09-15 ES ES02016936T patent/ES2305157T3/es not_active Expired - Lifetime
- 1997-09-15 AU AU42154/97A patent/AU728581B2/en not_active Ceased
-
2008
- 2008-04-10 US US12/101,107 patent/US7790696B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE395904T1 (de) | 2008-06-15 |
AU728581B2 (en) | 2001-01-11 |
KR100507660B1 (ko) | 2005-08-10 |
DE69717661D1 (de) | 2003-01-16 |
EP0938298A1 (en) | 1999-09-01 |
EP1254657A2 (en) | 2002-11-06 |
EP1254657B1 (en) | 2008-05-21 |
CN1138533C (zh) | 2004-02-18 |
CA2271388C (en) | 2007-11-06 |
ATE228824T1 (de) | 2002-12-15 |
US20080286353A1 (en) | 2008-11-20 |
US7790696B2 (en) | 2010-09-07 |
DE69738719D1 (de) | 2008-07-03 |
EP1254657A3 (en) | 2003-03-05 |
CA2271388A1 (en) | 1998-03-19 |
AU4215497A (en) | 1998-04-02 |
ES2305157T3 (es) | 2008-11-01 |
KR20000036088A (ko) | 2000-06-26 |
EP0938298B1 (en) | 2002-12-04 |
CN1237102A (zh) | 1999-12-01 |
WO1998010748A1 (en) | 1998-03-19 |
JP2001502299A (ja) | 2001-02-20 |
DE69717661T2 (de) | 2003-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2187812T3 (es) | Composicion de liposomas. | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
ATE475668T1 (de) | Immunisierung durch impfung von dns transkriptionseinheit | |
NO20001768L (no) | Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav | |
GB9828000D0 (en) | Antigens | |
AU6803298A (en) | Vaccines | |
DE69739253D1 (de) | Liposomaler grippeimpfstoff und verfahren | |
MY113428A (en) | Hepatitis b vaccine | |
DE69534778D1 (en) | Cathepsin-02-protease | |
CA2185470A1 (en) | Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes | |
AU1013601A (en) | Method of inducing and/or enhancing an immune response to tumor antigens | |
EP0904393A4 (en) | PARAPOXVIRUS VECTORS | |
EP0934083A4 (en) | IMPROVED VACCINES | |
ES2151506T3 (es) | Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos. | |
WO1999025861A3 (fr) | Vecteurs adenoviraux et methode de reduction des evenements de recombinaison homologue | |
AU3926097A (en) | Improved inactivated vaccines | |
NO972219D0 (no) | Immunogenpreparater | |
AU1991097A (en) | Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases | |
CY2540B1 (en) | Vaccine against mumps containing a jeryl-lynn virus strain | |
GB9818133D0 (en) | Vaccine | |
WO1993017115A3 (en) | Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it | |
WO1999016466A3 (en) | Vaccine compositions and methods of enhancing vaccine efficacy | |
WO1997029194A3 (de) | Herstellung von l-ascorbinsäure | |
EP1518927A3 (en) | Optimization of immunomodulatory properties of genetic vaccines | |
ITCS980003U4 (it) | Sistema aeritermomeccanico per la produzione di aria calda ottenuta bruciando legna, per il riscaldamento di ambienti. |